Scholarlink

Background <p>While loss of Y chromosome (LOY), a common somatic alteration with aging, has been associated with cardiovascular diseases, its specific impact on ST-segment elevation myocardial infarction (STEMI) remains underexplored.</p> Methods <p>This study enrolled 928 males undergoing primary percutaneous coronary intervention for STEMI to investigate the impact of LOY in blood cells on all-cause mortality. LOY was measured in males using droplet digital polymerase chain reaction technique. The primary outcome was all-cause mortality.</p> Results <p>During a median of 3.99-year follow-up, 93 males (10.0%) died. Of these, 39 (4.2%) died within 1 year, 56 (6.0%) within 2 years, and 67 (7.2%) within 3 years. Compared to males with LOY &lt; 18% (the 90th percentile), those with LOY ≥ 18% had an increased mortality after multivariable adjustment including age, with adjusted hazard ratios (HRs) of 2.45 (95% confidence interval [CI]: 1.16–5.15; <i>P</i> = 0.018), 2.11 (95% CI: 1.11–4.01; <i>P</i> = 0.024), and 1.88 (95% CI: 1.02–3.45; <i>P</i> = 0.043) at 1-, 2-, and 3-year follow-up, respectively. Among males without prior MI, those with LOY ≥ 18% have higher mortality than those with LOY &lt; 18% (adjusted HR 1.93; 95% CI: 1.01–3.67; <i>P</i> = 0.045), whereas no significant association is observed in males with prior MI.</p> Conclusions <p>LOY ( ≥ 18%) is associated with an increased 1-, 2-, and 3-year mortality in male STEMI patients and may serve as a potential biomarker for risk stratification.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Age-related loss of Y chromosome is associated with mortality after ST-segment elevation myocardial infarction

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月3日

查看全文
  • Nan Li,
  • Jiannan Li,
  • Yu Tan,
  • Runzhen Chen,
  • Xiaoxiao Zhao,
  • Peng Zhou,
  • Chen Liu,
  • Jinying Zhou,
  • Yi Chen,
  • Shaodi Yan,
  • Hanjun Zhao,
  • Li Song,
  • Hongbing Yan

摘要

Background

While loss of Y chromosome (LOY), a common somatic alteration with aging, has been associated with cardiovascular diseases, its specific impact on ST-segment elevation myocardial infarction (STEMI) remains underexplored.

Methods

This study enrolled 928 males undergoing primary percutaneous coronary intervention for STEMI to investigate the impact of LOY in blood cells on all-cause mortality. LOY was measured in males using droplet digital polymerase chain reaction technique. The primary outcome was all-cause mortality.

Results

During a median of 3.99-year follow-up, 93 males (10.0%) died. Of these, 39 (4.2%) died within 1 year, 56 (6.0%) within 2 years, and 67 (7.2%) within 3 years. Compared to males with LOY < 18% (the 90th percentile), those with LOY ≥ 18% had an increased mortality after multivariable adjustment including age, with adjusted hazard ratios (HRs) of 2.45 (95% confidence interval [CI]: 1.16–5.15; P = 0.018), 2.11 (95% CI: 1.11–4.01; P = 0.024), and 1.88 (95% CI: 1.02–3.45; P = 0.043) at 1-, 2-, and 3-year follow-up, respectively. Among males without prior MI, those with LOY ≥ 18% have higher mortality than those with LOY < 18% (adjusted HR 1.93; 95% CI: 1.01–3.67; P = 0.045), whereas no significant association is observed in males with prior MI.

Conclusions

LOY ( ≥ 18%) is associated with an increased 1-, 2-, and 3-year mortality in male STEMI patients and may serve as a potential biomarker for risk stratification.